RE:RE:RE:RE:RE: Pelareorep + Paclitaxel = ADC/HER2 failed breast cancerMay 21, 2024 - - Roche Holding AG said an experimental breast-cancer treatment will get an expedited review from US regulators after showing it helped patients live longer without the disease progressing. The decision is based on research showing the medicine, called inavolisib, could offer a more effective first treatment option for women with a ER+/HER2 - (negative) breast cancer mutation.
The potential treatment for women with mutations called PIK3CA, is found in about 40% of hormone-positive breast cancers.
https://www.onclive.com/view/inavolisib-receives-fda-breakthrough-therapy-designation-for-pik3ca-mutated-hr-her2-breast-cancer